Therapeutic approaches in myositis

Current Rheumatology Reports

Volumn 13, Issue 3, 2011, Pages 182-191

  Aggarwal, Rohit ^a   Oddis, Chester V ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Dermatomyositis; Polymyositis; Treatment

Indexed keywords

ALUMINUM HYDROXIDE; AZATHIOPRINE; CHLORAMBUCIL; COLCHICINE; CORTICOSTEROID; CREATINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DILTIAZEM; ECULIZUMAB; ETANERCEPT; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; INFLIXIMAB; ISOTRETINOIN; MEPACRINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIMECROLIMUS; PLACEBO; PREDNISOLONE; PREDNISONE; PROBENECID; RITUXIMAB; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR INHIBITOR; UNINDEXED DRUG; WARFARIN;

ARTICLE; BONE MARROW SUPPRESSION; CALCINOSIS; CATARACT; CELLULAR IMMUNITY; CORTICOSTEROID INDUCED MYOPATHY; DERMATOMYOSITIS; DISABILITY; DISEASE SEVERITY; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG TOLERABILITY; DYSPHAGIA; ESOPHAGEAL DYSPHAGIA; GASTROINTESTINAL DISEASE; GASTROINTESTINAL INTOLERANCE; GASTROINTESTINAL SYMPTOM; GLAUCOMA; HUMAN; HYPERKALEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; INTERSTITIAL LUNG DISEASE; JUVENILE DERMATOMYOSITIS; LIVER TOXICITY; LOW DRUG DOSE; MALAISE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; OSTEOPOROSIS; PANCREATITIS; PHYSIOTHERAPY; PLASMAPHERESIS; POLYMYOSITIS; RASH; RECOMMENDED DRUG DOSE; REHABILITATION CARE; REMISSION; SIDE EFFECT; SKIN DISEASE; T LYMPHOCYTE; TREATMENT RESPONSE; TREMOR; VOMITING;

CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYOSITIS; TREATMENT OUTCOME;

EID: 79957438836     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-011-0172-z     Document Type: Article

References (57)

1. SM Sultan E Allen CV Oddis, et al. 2008 Reliability and validity of the myositis disease activity assessment tool Arthritis Rheum 58 11 3593 3599 18975333 10.1002/art.23963
2. A Nzeusseu F Brion C Lefebvre P Knoops JP Devogelaer FA Houssiau 1999 Functional outcome of myositis patients: can a low-dose glucocorticoid regimen achieve good functional results? Clin Exp Rheumatol 17 4 441 446 10464554 1:STN:280:DyaK1Mzptlyhsg%3D%3D (Pubitemid 29343628)
3. MM Joffe LA Love RL Leff, et al. 1993 Drug therapy of the idiopathic inflammatory myopathies: predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy Am J Med 94 4 379 387 8386437 10.1016/0002-9343(93)90148-I 1:STN:280:DyaK3s3jsFylsw%3D%3D (Pubitemid 23106624)
4. J Miller Y Walsh S Saminaden 2002 Randomised double blind controlled trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy J Neurol Sci 199 Suppl 1 S53
5. J Vencovsky K Jarosova S Machacek, et al. 2000 Cyclosporine A versus methotrexate in the treatment of polymyositis and dermatomyositis Scand J Rheumatol 29 2 95 102 10777122 10.1080/030097400750001897 1:STN:280: DC%2BD3c3js1yrsg%3D%3D (Pubitemid 30434151)
6. L Villalba JE Hicks EM Adams, et al. 1998 Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens Arthritis Rheum 41 3 392 399 9506565 10.1002/1529-0131(199803)41:3<392::AID-ART3>3. 0.CO;2-X 1:CAS:528:DyaK1cXitF2itr4%3D (Pubitemid 28128762)
7. CV Oddis FC Sciurba KA Elmagd TE Starzl 1999 Tacrolimus in refractory polymyositis with interstitial lung disease Lancet 353 9166 1762 1763 10347992 10.1016/S0140-6736(99)01927-3 1:STN:280:DyaK1M3nsFOnug%3D%3D (Pubitemid 29240378)
8. MR Wilkes SM Sereika N Fertig MR Lucas CV Oddis 2005 Treatment of antisynthetase-associated interstitial lung disease with tacrolimus Arthritis Rheum 52 8 2439 2446 16052580 10.1002/art.21240 1:CAS:528:DC%2BD2MXpslGht7w%3D (Pubitemid 41117430)
9. MC Dalakas R Hohlfeld 2003 Polymyositis and dermatomyositis Lancet 362 9388 971 982 14511932 10.1016/S0140-6736(03)14368-1 1:CAS:528: DC%2BD3sXnsVWqu7g%3D (Pubitemid 37159295)
10. P Cherin S Pelletier A Teixeira, et al. 2002 Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients Arthritis Rheum 46 2 467 474 11840450 10.1002/art.10053 1:CAS:528:DC%2BD38XhvF2qsr0%3D (Pubitemid 34136585)
11. MG Danieli G Malcangi C Palmieri, et al. 2002 Cyclosporin A and intravenous immunoglobulin treatment in polymyositis/dermatomyositis Ann Rheum Dis 61 1 37 41 11779756 10.1136/ard.61.1.37 1:CAS:528:DC%2BD38XntFamsg%3D%3D (Pubitemid 34074837)
12. C Manlhiot PN Tyrrell L Liang AR Atkinson W Lau BM Feldman 2008 Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content Pediatrics 121 3 e626 e630 18299304 10.1542/peds.2007-1218
13. M Mosca F Strigini A Carmignani A D'Ascanio AR Genazzani S Bombardieri 2005 Pregnant patient with dermatomyositis successfully treated with intravenous immunoglobulin therapy Arthritis Rheum 53 1 119 121 15696574 10.1002/art.20913 1:STN:280:DC%2BD2M7hs1Krug%3D%3D (Pubitemid 40216362)
14. J Rowin AA Amato N Deisher J Cursio MN Meriggioli 2006 Mycophenolate mofetil in dermatomyositis: is it safe? Neurology 66 8 1245 1247 16636243 10.1212/01.wnl.0000208416.32471.c0 1:CAS:528:DC%2BD28XjtFOrtLo%3D (Pubitemid 43739712)
15. V Majithia V Harisdangkul 2005 Mycophenolate mofetil (CellCept): an alternative therapy for autoimmune inflammatory myopathy Rheumatology (Oxford) 44 3 386 389 10.1093/rheumatology/keh499 1:CAS:528:DC%2BD2MXhslSksLw%3D (Pubitemid 40361299)
16. CN Pisoni MJ Cuadrado MA Khamashta GR Hughes DP D'Cruz 2007 Mycophenolate mofetil treatment in resistant myositis Rheumatology (Oxford) 46 3 516 518 10.1093/rheumatology/kel336 1:CAS:528:DC%2BD2sXhvFWlurc%3D (Pubitemid 46344667)
17. MA Waldman JP Callen 2004 Self-resolution of Epstein-Barr virus-associated B-cell lymphoma in a patient with dermatomyositis following withdrawal of mycophenolate mofetil and methotrexate J Am Acad Dermatol 51 2 Suppl S124 S130 15280831 10.1016/j.jaad.2004.03.020
18. JC Edge JD Outland JR Dempsey JP Callen 2006 Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis Arch Dermatol 142 1 65 69 16415388 10.1001/archderm.142.1.65 1:CAS:528: DC%2BD28XhtVOjsb0%3D (Pubitemid 43107363)
19. KA Rouster-Stevens GA Morgan D Wang LM Pachman 2010 Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis Arthritis Care Res (Hoboken) 62 10 1446 1451 10.1002/acr.20269
20. ME Cronin FW Miller JE Hicks M Dalakas PH Plotz 1989 The failure of intravenous cyclophosphamide therapy in refractory idiopathic inflammatory myopathy J Rheumatol 16 9 1225 1228 2681763 1:STN:280:DyaK3c%2FktVGnsQ%3D%3D (Pubitemid 19260112)
21. PA Sinoway JP Callen 1993 Chlorambucil. An effective corticosteroid- sparing agent for patients with recalcitrant dermatomyositis Arthritis Rheum 36 3 319 324 8452575 10.1002/art.1780360305 1:STN:280:DyaK3s7pvFGktg%3D%3D (Pubitemid 23090597)
22. Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label prospective study. J Rheumatol. 2007;34(9):1864-8. This article describes the efficacy of rituximab in refractory polymyositis patients. (Pubitemid 350067647)
23. R Valiyil L Casciola-Rosen G Hong A Mammen L Christopher-Stine 2010 Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series Arthritis Care Res (Hoboken) 62 9 1328 1334 10.1002/acr.20219 1:CAS:528:DC%2BC3cXht1Kru7rL
24. Deligny C, Goeb V, Dueymes M, et al. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Comment on the article by Valiyil et al. Arthritis Care Res. (Hoboken) 2010, Oct 27 (Epub ahead of print).
25. BR Whelan DA Isenberg 2009 Poor response of anti-SRP-positive idiopathic immune myositis to B-cell depletion Rheumatology (Oxford) 48 5 594 595 10.1093/rheumatology/kep027
26. JB Arlet D Dimitri C Pagnoux, et al. 2006 Marked efficacy of a therapeutic strategy associating prednisone and plasma exchange followed by rituximab in two patients with refractory myopathy associated with antibodies to the signal recognition particle (SRP) Neuromuscul Disord 16 5 334 336 16616848 10.1016/j.nmd.2006.03.002
27. L Chung MC Genovese DF Fiorentino 2007 A pilot trial of rituximab in the treatment of patients with dermatomyositis Arch Dermatol 143 6 763 767 17576943 10.1001/archderm.143.6.763 1:CAS:528:DC%2BD2sXns1ejsbs%3D (Pubitemid 46955736)
28. TD Levine 2005 Rituximab in the treatment of dermatomyositis: an open-label pilot study Arthritis Rheum 52 2 601 607 15692974 10.1002/art.20849 1:CAS:528:DC%2BD2MXit1Gjtb0%3D (Pubitemid 40216325)
29. HV Dinh C McCormack S Hall HM Prince 2007 Rituximab for the treatment of the skin manifestations of dermatomyositis: a report of 3 cases J Am Acad Dermatol 56 1 148 153 17097377 10.1016/j.jaad.2006.05.068 (Pubitemid 44969291)
30. S Sanchez-Ramon JC Ravell I de la Torre, et al. 2010 Long-term remission of severe refractory dermatopolymyositis with a weekly-scheme of immunoglobulin followed by rituximab therapy Rheumatol Int 30 6 817 819 19536548 10.1007/s00296-009-1000-x
31. MA Cooper DL Willingham DE Brown AR French FF Shih AJ White 2007 Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients Arthritis Rheum 56 9 3107 3111 17763414 10.1002/art.22856 1:CAS:528:DC%2BD2sXht1GgtbrN (Pubitemid 47502758)
32. CV Oddis AM Reed R Aggarwal 2010 Rituximab in the treatment of refractory adult and juvenile dermatomyositis (DM) and adult polymyositis (PM)-The RIM Study Arthritis Res 62 12 (Suppl) 3844 This was the first randomized controlled trial on rituximab use in myositis, published in abstract form for the 2010 Annual American College of Rheumatology Meeting
33. P Efthimiou 2006 Tumor necrosis factor-α in inflammatory myopathies: pathophysiology and therapeutic implications Semin Arthritis Rheum 36 3 168 172 16970978 10.1016/j.semarthrit.2006.07.003 1:CAS:528: DC%2BD28XhtFOiu7nL (Pubitemid 44691885)
34. P Efthimiou S Schwartzman LJ Kagen 2006 Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients Ann Rheum Dis 65 9 1233 1236 16476710 10.1136/ard.2005.048744 1:CAS:528:DC%2BD28XpvVensLs%3D (Pubitemid 44277404)
35. M Dastmalchi C Grundtman H Alexanderson, et al. 2008 A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies Ann Rheum Dis 67 12 1670 1677 18272672 10.1136/ard.2007.077974 1:CAS:528:DC%2BD1MXjs1OitA%3D%3D
36. K Coyle A Pokrovnichka K French 2008 A randomized double blind placebo controlled trial of infliximab in patients with polymyositis and dermatomyositis Arthritis Res 58 9 S293
37. GJ Hengstman JL De Bleecker E Feist, et al. 2008 Open-label trial of anti-TNF-alpha in dermato- and polymyositis treated concomitantly with methotrexate Eur Neurol 59 3-4 159 163 18230873 10.1159/000114036 1:CAS:528:DC%2BD1cXit1yntb0%3D This article describes open-label use of an anti-TNF drug in the treatment of myositis (Pubitemid 351301260)
38. F Iannone C Scioscia PC Falappone M Covelli G Lapadula 2006 Use of etanercept in the treatment of dermatomyositis: a case series J Rheumatol 33 9 1802 1804 16960940 1:CAS:528:DC%2BD28XhtVGisr3P (Pubitemid 44373214)
39. RJ Barohn L Herbelin JT Kissel, et al. 2006 Pilot trial of etanercept in the treatment of inclusion-body myositis Neurology 66 2 Suppl 1 S123 S124 16432140 1:CAS:528:DC%2BD28Xht1Kquw%3D%3D
40. M Harigai M Hara N Kamatani S Kashiwazaki 1999 Nation-wide survey for the treatment with cyclosporin A of interstitial pneumonia associated with collagen diseases Ryumachi 39 6 819 828 10695405 1:STN:280:DC%2BD3c7lvFOhug%3D%3D (Pubitemid 30141307)
41. T Kotani S Makino T Takeuchi, et al. 2008 Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis J Rheumatol 35 2 254 259 18085732 1:CAS:528:DC%2BD1cXjtFamtr0%3D (Pubitemid 351284439)
42. K Takada K Nagasaka N Miyasaka 2005 Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with T-cell-specific immunosuppressants Autoimmunity 38 5 383 392 16227154 10.1080/08916930500124023 1:CAS:528:DC%2BD2MXhtFWhtLbK (Pubitemid 41358669)
43. H Takizawa K Ito 1997 Cyclophosphamide pulse therapy for rapidly progressive interstitial pneumonia in dermatomyositis. A new possibility for rescue? Intern Med 36 7 448 449 9240490 10.2169/internalmedicine.36.448 1:STN:280:DyaK2szot1CrtA%3D%3D (Pubitemid 27349308)
44. H Kameda H Nagasawa H Ogawa, et al. 2005 Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis J Rheumatol 32 9 1719 1726 16142867 1:CAS:528:DC%2BD2MXhtFSktb7M (Pubitemid 41324810)
45. I Kobayashi M Yamada Y Takahashi, et al. 2003 Interstitial lung disease associated with juvenile dermatomyositis: clinical features and efficacy of cyclosporin A Rheumatology (Oxford) 42 2 371 374 10.1093/rheumatology/keg040 1:STN:280:DC%2BD3s%2FosVCktA%3D%3D (Pubitemid 36305628)
46. K Takada J Kishi N Miyasaka 2007 Step-up versus primary intensive approach to the treatment of interstitial pneumonia associated with dermatomyositis/polymyositis: a retrospective study Mod Rheumatol 17 2 123 130 17437167 10.1007/s10165-007-0553-3 (Pubitemid 46614356)
47. PA Morganroth ME Kreider VP Werth 2010 Mycophenolate mofetil for interstitial lung disease in dermatomyositis Arthritis Care Res (Hoboken) 62 10 1496 1501 10.1002/acr.20212
48. LA Saketkoo LR Espinoza 2009 Experience of mycophenolate mofetil in 10 patients with autoimmune-related interstitial lung disease demonstrates promising effects Am J Med Sci 337 5 329 335 19295413 10.1097/MAJ. 0b013e31818d094b This was the first report of a good case series regarding potential use of MMF in the treatment of ILD
49. M Sem O Molberg MB Lund JT Gran 2009 Rituximab treatment of the anti-synthetase syndrome: a retrospective case series Rheumatology (Oxford) 48 8 968 971 10.1093/rheumatology/kep157 1:CAS:528:DC%2BD1MXht1ajtrfL This article describes the efficacy of rituximab in the treatment of antisynthetase syndrome
50. F Frikha A Rigolet A Behin B Fautrel S Herson O Benveniste 2009 Efficacy of rituximab in refractory and relapsing myositis with anti-JO1 antibodies: a report of two cases Rheumatology (Oxford) 48 9 1166 1168 10.1093/rheumatology/ kep147 1:CAS:528:DC%2BD1MXht1WisLvO
51. S Mii S Niiyama M Kusunoki S Arai K Katsuoka 2006 Cyclosporine A as treatment of esophageal involvement in dermatomyositis Rheumatol Int 27 2 183 185 16900376 10.1007/s00296-006-0168-6 1:CAS:528:DC%2BD2sXivFOgsA%3D%3D (Pubitemid 46088278)
52. I Marie JF Menard PY Hatron, et al. 2010 Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients Arthritis Care Res (Hoboken) 62 12 1748 1755 10.1002/acr.20325 1:STN:280:DC%2BC3M%2FgsFKntg%3D%3D
53. FW Miller SF Leitman ME Cronin, et al. 1992 Controlled trial of plasma exchange and leukapheresis in polymyositis and dermatomyositis N Engl J Med 326 21 1380 1384 1472183 10.1056/NEJM199205213262102 1:STN:280:DyaK383js1Ojug%3D%3D
54. GA Nader IE Lundberg 2009 Exercise as an anti-inflammatory intervention to combat inflammatory diseases of muscle Curr Opin Rheumatol 21 6 599 603 19726993 10.1097/BOR.0b013e3283319d53 1:CAS:528:DC%2BD1MXht1WmtrjN
55. T Kazuki S Bookbinder R Furie 2002 A pilot study of eculizumab in patients with dermatomyositis Arthritis Res 46 Suppl S489
56. YL Chung H Alexanderson N Pipitone, et al. 2007 Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: six-month, double-blind, randomized, placebo-controlled trial Arthritis Rheum 57 4 694 702 17471547 10.1002/art.22687 1:CAS:528:DC%2BD2sXmtFKhs70%3D (Pubitemid 46764062)
57. N Schleinitz E Jean L Benarous, et al. 2008 Subcutaneous immunoglobulin administration: an alternative to intravenous infusion as adjuvant treatment for dermatomyositis? Clin Rheumatol 27 8 1067 1068 18463936 10.1007/s10067-008- 0892-2